DOI QR코드

DOI QR Code

Serum nitrotyrosine concentration in dogs with myxomatous mitral valve disease

  • Kim, Jun-Seok (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Jun-Seok (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Hyung-Jin (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2016.09.26
  • 심사 : 2017.01.31
  • 발행 : 2017.03.31

초록

The aim of this study was to compare serum nitrotyrosine concentrations in healthy dogs with those in dogs with myxomatous mitral valve disease (MMVD). Fifty client-owned dogs were included in this study. Based on echocardiographic results, dogs were categorized into healthy (control), mild-, moderate-, and severe-MMVD groups. Serum nitrotyrosine concentrations were determined from enzyme-linked immunosorbent assays. No significant difference between control dogs and dogs with mild MMVD was detected (p = 0.31). However, dogs with moderate MMVD had significantly higher serum concentrations of nitrotyrosine (p = 0.04) than that in controls, and dogs with severe MMVD had significantly lower serum concentrations of nitrotyrosine (p = 0.03) than that in moderate MMVD dogs. There were negative correlations in the association of serum nitrotyrosine with age (n = 30, $R^2=0.067$, p = 0.27), left atrial-to-aortic root diameter ratio (n = 30, $R^2=0.02$, p = 0.57), and platelet count (n = 30, $R^2=0.39$, p = 0.003); however, only the platelet correlation was significant. Among dogs with MMVD, there was no significant difference in serum nitrotyrosine concentration between males and females. The results of this study suggest that tyrosine nitration end-products might be potential biomarkers for the detection of MMVD in dogs.

키워드

참고문헌

  1. Boswood A. Biomarkers in cardiovascular disease: beyond natriuretic peptides. J Vet Cardiol 2009, 11 (Suppl 1), S23-32. https://doi.org/10.1016/j.jvc.2009.01.003
  2. Brown CH 3rd, Leverett LB, Lewis CW, Alfrey CP Jr, Hellums JD. Morphological, biochemical, and functional changes in human platelets subjected to shear stress. J Lab Clin Med 1975, 86, 462-471.
  3. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001, 89, 279-286. https://doi.org/10.1161/hh1501.094115
  4. Cunningham SM, Rush JE, Freeman LM. Systemic inflammation and endothelial dysfunction in dogs with congestive heart failure. J Vet Intern Med 2012, 26, 547-557. https://doi.org/10.1111/j.1939-1676.2012.00923.x
  5. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998, 32, 955-963. https://doi.org/10.1016/S0735-1097(98)00336-2
  6. Feng Q, Lu X, Jones DL, Shen J, Arnold JMO. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001, 104, 700-704. https://doi.org/10.1161/hc3201.092284
  7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288, 373-376. https://doi.org/10.1038/288373a0
  8. Gibbs CR, Blann AD, Watson RDS, Lip GYH. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and ${\beta}$-blocker therapy. Circulation 2001, 103, 1746-1751. https://doi.org/10.1161/01.CIR.103.13.1746
  9. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 1997, 411, 157-160. https://doi.org/10.1016/S0014-5793(97)00469-9
  10. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996, 93, 1087-1094. https://doi.org/10.1161/01.CIR.93.6.1087
  11. Heymes C, Vanderheyden M, Bronzwaer JGF, Shah AM, Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999, 99, 3009-3016. https://doi.org/10.1161/01.CIR.99.23.3009
  12. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999, 43, 562-571. https://doi.org/10.1016/S0008-6363(99)00169-8
  13. de Laforcade AM, Freeman LM, Rush JE. Serum nitrate and nitrite in dogs with spontaneous cardiac disease. J Vet Intern Med 2003, 17, 315-318. https://doi.org/10.1111/j.1939-1676.2003.tb02454.x
  14. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994, 120, 227-237. https://doi.org/10.7326/0003-4819-120-3-199402010-00009
  15. Mow T, Pedersen HD. Increased endothelin-receptor density in myxomatous canine mitral valve leaflets. J Cardiovasc Pharmacol 1999, 34, 254-260. https://doi.org/10.1097/00005344-199908000-00011
  16. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, Schulz R, Butanny J, Stewart DJ, Husain M. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002, 109, 735-743. https://doi.org/10.1172/JCI0213265
  17. Nakazawa H, Fukuyama N, Takizawa S, Tsuji C, Yoshitake M, Ishida H. Nitrotyrosine formation and its role in various pathological conditions. Free Radical Res 2000, 33, 771-784. https://doi.org/10.1080/10715760000301291
  18. Oyama Ji, Shimokawa H, Momii H, Cheng X, Fukuyama N, Arai Y, Egashira K, Nakazawa H, Takeshita A. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 1998, 101, 2207-2214. https://doi.org/10.1172/JCI986
  19. Pedersen HD, Schutt T, Sondergaard R, Qvortrup K, Olsen LH, Kristensen AT. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003, 17, 178-184. https://doi.org/10.1111/j.1939-1676.2003.tb02431.x
  20. Tarnow I, Kristensen AT, Texel H, Olsen LH, Pedersen HD. Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2003, 17, 680-686. https://doi.org/10.1111/j.1939-1676.2003.tb02500.x
  21. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010, 333, 191-201. https://doi.org/10.1007/s11010-009-0219-x
  22. Zuppiroli A, Cecchi F, Ciaccheri M, Italiani G, Dolara A, Longo G, Matucci M, Morfini M, Rafanelli D. Platelet function and coagulation studies in patients with mitral valve prolapse. Clin Cardiol 1986, 9, 487-492. https://doi.org/10.1002/clc.4960091004

피인용 문헌

  1. Serum Concentration of Nitrotyrosine as Indicator of Disease Progress in Dogs with Myxomatous Mitral Valve Disease vol.36, pp.2, 2019, https://doi.org/10.17555/jvc.2019.04.36.2.102